-+ 0.00%
-+ 0.00%
-+ 0.00%

CELLDEX THERAPEUTICS - PHASE 2 BARZOLVOLIMAB STUDY IN ATOPIC DERMATITIS DID NOT MEET KEY EFFICACY MEASURES

Reuters·11/19/2026 21:22:40